Dr Rebecca Kristeleit specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy's and St Thomas' NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy's Clinical Research Facility. She currently leads a large portfolio of Phase I-III clinical studies including immunotherapy for gynaecological malignancies.
Dr Kristeleit qualified in 1995 from the University of Manchester after initially completing a BSc in medical science at the University of St Andrews. As an undergraduate, she was awarded an ERASMUS Scholarship which allowed her to study in Switzerland before completing an elective at Massachusetts General Hospital, Harvard University. She specialised in medical oncology at the Royal Marsden Hospital and obtained a CRUK-funded clinical research fellowship at the Institute of Cancer Research, being awarded a PhD in the clinical pharmacology of HDAC inhibitors. She completed a Senior Fellowship at the Royal Marsden Hospital's Drug Development Unit in 2009 where she gained experience in experimental therapeutics. She was appointed Clinical Senior Lecturer and Honorary Consultant Medical Oncologist at UCL in 2009 and subsequently Associate Professor in Experimental Therapeutics at UCL.
Dr Kristeleit is a member of the Target Ovarian Cancer Scientific Advisory Board, the Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, and has been elected to the ESMO Faculty from 2021 to 2025. She has over 100 peer-reviewed publications and is often asked to speak at national and international conferences as well as advise pharmaceutical companies on their gynaecological cancer drug development.
Dr Kristeleit has previously served as Chair of the BGCS Scientific Committee, the UK Oncology Forum Gynaecology Track, and the ASCO Gynaecological Cancer Scientific Committee.
